Abbott Laboratories (ABT)

Abbott Laboratories' stock price has declined over the past six months, with a share price of $102.72 as of April 9, 2026, a 17.49% decrease from April 10, 2025. The stock hit a 52-week and 20-month low on April 10, 2026. A jury ordered Abbott to pay $70 million in damages related to its premature infant formula causing necrotizing enterocolitis, raising concerns about potential litigation risks. Goldman Sachs lowered its price target for ABT to $121.00 from $140.00, while maintaining a 'Buy' rating. The Nutrition segment showed weakness with a 9.1% organic sales decline in Q4 2025. Abbott completed its acquisition of Exact Sciences, expected to contribute $3 billion in incremental sales by 2026 but dilute 2026 adjusted earnings per share by about $0.20. Investors are looking ahead to Abbott's first-quarter 2026 earnings release, scheduled for April 16, 2026.

While general information about seasonal stock returns for ABT exists, detailed information on the demand seasonality for Abbott Laboratories' individual products and services is not explicitly available. The healthcare sector can experience some seasonality related to illness trends, but a diversified company like Abbott may have a more balanced demand profile throughout the year. The company focuses on long-term growth through research and development and expansion into emerging markets.

Abbott Laboratories is a multinational medical devices and healthcare company headquartered in Abbott Park, Illinois, operating in the healthcare sector with a focus on medical devices and pharmaceuticals. The company's business is divided into four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. These segments offer a range of products including branded generic medicines, diagnostic systems and tests, pediatric and adult nutrition products, and various medical devices.

Abbott Laboratories has a global presence, operating in over 160 countries with its headquarters in Abbott Park, Illinois. The company has manufacturing facilities, R&D centers, commercial offices, and distribution networks across various regions. Key operational sites include locations in the San Francisco Bay Area, Donegal (Ireland), Witney (United Kingdom), Wiesbaden (Germany), and Singapore. Abbott has a strong presence in Europe and Asia Pacific, with key geographies including the U.S., Germany, China, Japan, India, Switzerland, and Canada.

Abbott Laboratories has maintained a strong brand reputation, recognized for innovation, social responsibility, and management effectiveness. The company has received awards and rankings, including being ranked on the Wall Street Journal's Management Top 250 list, Fortune's list of the Most Innovative Companies in America, and the JUST 100 list. Abbott was also named among industry leaders on the Dow Jones Sustainability Index for the 20th consecutive year and earned five 2025 Edison Best New Product Awards. However, the legal ruling in April 2026, where Abbott was ordered to pay $70 million in damages for its premature infant formula causing NEC, has negatively impacted the company's reputation.

Abbott Laboratories is primarily owned by institutional investors, holding approximately 79% to 82.27% of the shares, while the general public holds around 20%. Insiders own under 1% to 1.16% of the company. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., State Street Corp, Capital International Investors, J. Stern & Co. LLP, Capital Research Global Investors, Geode Capital Management, Llc, Morgan Stanley, Norges Bank, and Wellington Management Group Llp.